IP Library Granted Patent US 7,176,277
Granted Patent B2
US 7,176,277 · App. 11/245,845 · Granted Feb 13, 2007

Conversion of apoptotic proteins

Assignee: The Burnham Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,176,277
App. No.
11/245,845
Granted
Feb 13, 2007
Kind
B2
Abstract

Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-X L are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.

Claims (3)

1. An isolated compound which binds to Bcl-2 protein and modulates the activity of said Bcl-2 protein in a cell so as to be inductive of apoptosis, without cleaving the Bcl-2 protein, wherein said compound consists of the 69 amino acids between amino acids 467 and 536 of the human TR3 receptor of SEQ ID NO: 3.

2. The compound of claim 1 wherein said compound induces a conformational change in Bcl-2.

3. The compound of claim 1 , wherein the compound comprises at least one D-amino acid.

Assignments (1)
CONFIRMATORY LICENSE Recorded Aug 12, 2019
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 050024/0606 →
Continuity (3)
Continuation 1073541800 · Dec 11, 2003
Provisional Application 6043353500 · Dec 12, 2002
Related Publication 20060193864A1 · Aug 31, 2006